Skip to content
10-K

Annual Report

Zevra Therapeutics, Inc. ZVRA

0001437749-25-007320

← back to feed
Filed
Mar 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 7, 2025 54.12M sh
Stock Repurchased FY 2024 · Dec 31, 2024 $0
Stock Repurchased FY 2024 · Dec 31, 2023 $3.45M
Capex FY 2024 · Dec 31, 2023 $296K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$33.54M
Long Term Debt FY 2024 · Dec 31, 2023 $5.07M
Cash And Equivalents FY 2024 · Dec 31, 2023 $43.05M
Current Liabilities FY 2024 · Dec 31, 2023 $73.72M
Total Liabilities FY 2024 · Dec 31, 2023 $110.46M
Current Assets FY 2024 · Dec 31, 2023 $86.94M
Total Assets FY 2024 · Dec 31, 2023 $172.33M
Eps Basic FY 2024 · Dec 31, 2023 −$1.30
Sga Expense FY 2024 · Dec 31, 2023 $34.31M
Net Income FY 2024 · Dec 31, 2023 −$46.05M
Operating Income FY 2024 · Dec 31, 2023 −$49.6M
Stockholders Equity restated FY 2024 · Dec 31, 2022 $75.12M